Equillium Inc. sell geldnutzer
Start price
12.04.22
/
50%
€2.81
Target price
12.04.23
€2.00
Performance (%)
-16.82%
End price
03.10.22
€2.33
Summary
This prediction ended on 03.10.22 with a price of €2.33. The prediction for Equillium Inc. closed with a convincing performance of -16.82%. geldnutzer has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Equillium Inc. | - | - | - |
iShares Core DAX® | -1.114% | 3.430% | 25.966% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% |
According to geldnutzer what are the pros and cons of Equillium Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
Capable Management
Good culture
Innovative
Small cyclical dependencies
Future proof or reliable business model
Cons
Risky balance sheet
High valuation
Very low/no dividend yield expected
Bad rating
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Few uniques
Dependend from some customers or products
Growths slower than the competition
Sustainability is not important
high free float
Below average Marketposition
Little known brand
Lower EBIT Margin than peer group
negative Cash Flow expected
Higher risks for its business
Comments by geldnutzer for this prediction
In the thread Equillium Inc. diskutieren
Sell mit Kursziel 2,0
In the thread Trading Equillium Inc.
Sell beendet
Stopped prediction by geldnutzer for Equillium Inc.
Equillium Inc.
Start price
Target price
Perf. (%)
€0.64
24.06.23
24.06.23
€1.60
24.06.24
24.06.24
-5.78%
25.06.24
25.06.24
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Risky balance sheet
Equillium Inc.
Start price
Target price
Perf. (%)
€0.52
11.03.23
11.03.23
€0.70
11.03.24
11.03.24
22.72%
24.06.23
24.06.23
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Risky balance sheet
Equillium Inc.
Start price
Target price
Perf. (%)
€2.33
03.10.22
03.10.22
€1.50
03.10.23
03.10.23
-77.66%
11.03.23
11.03.23
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Risky balance sheet
Equillium Inc.
Start price
Target price
Perf. (%)
€3.45
24.01.22
24.01.22
€4.00
24.01.23
24.01.23
-18.71%
12.04.22
12.04.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Risky balance sheet
Equillium Inc.
Start price
Target price
Perf. (%)
€3.94
20.12.21
20.12.21
€3.00
20.12.22
20.12.22
-12.39%
24.01.22
24.01.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Risky balance sheet
Equillium Inc.
Start price
Target price
Perf. (%)
€3.82
21.12.20
21.12.20
€6.00
21.12.21
21.12.21
3.14%
20.12.21
20.12.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Risky balance sheet
Equillium Inc.
Start price
Target price
Perf. (%)
€4.02
10.12.20
10.12.20
€3.50
10.12.21
10.12.21
-4.98%
21.12.20
21.12.20
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Risky balance sheet
Equillium Inc.
Start price
Target price
Perf. (%)
€4.42
23.11.20
23.11.20
€5.50
23.11.21
23.11.21
-9.05%
10.12.20
10.12.20
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Risky balance sheet
Equillium Inc.
Start price
Target price
Perf. (%)
€10.70
27.07.20
27.07.20
€3.50
04.11.21
04.11.21
-58.69%
23.11.20
23.11.20
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Risky balance sheet
Equillium Inc.
Start price
Target price
Perf. (%)
€12.50
13.07.20
13.07.20
€16.00
27.07.20
27.07.20
-14.40%
27.07.20
27.07.20
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Risky balance sheet